

SERUM INTERLEUKIN-8 IN EGYPTIAN B-THALASSEMIC CHILDREN



Thesis
Submitted for Partial Fulfillment
of Master Degree
in Pediatrics



By
MAHA MAHMOUD MAHMOUD EL-ATTAR
M.B., B.ch.

57223



Supervised by

ELALFY

DR. MOHSEN SALEH EL-ALFY

Asst. Prof. of Pediatrics
Faculty of Medicine
Ain Shams University

PROF. DR. ALI KHALIFA ALI

Prof. of Biochemistry
Head of Oncology Diagnostic Unit
Faculty of Medicine
Ain Shams University

A.S. 7/6/

DR. AISHA ALI FAKEER

Asst. Prof. of Clinical Pathology
Faculty of Medicine
Ain Shams University

6/8/98 MS
M.A

Amal El Bushkha

**Faculty of Medicine
Ain Shams University**

1995

TO
MY
MOTHER,
FATHER,
SISTERS
AND
HUSBAND



ACKNOWLEDGMENT

I WOULD LIKE TO EXPRESS MY DEEPEST APPRECIATION AND SINCERE GRATITUDE TO DR. MOHSEN SALEH EL-ALFY, ASSISTANT PROFESSOR OF PEDIATRICS, AIN SHAMS UNIVERSITY FOR HIS SUPERVISION, SUPPORT AND KIND ENCOURAGEMENT. HIS ADVICE AND ENTHUSIASM WERE ESPECIALLY ESSENTIAL TO COMPLETE THIS WORK.

MY UTMOST THANKS AND APPRECIATION ARE DUE TO PROF. DR. ALI KHALIFA ALI, PROFESSOR OF BIOCHEMISTRY AND HEAD OF TUMOR MARKERS DEPARTMENT, AIN SHAMS UNIVERSITY, FOR HIS SUPERVISION, INVALUABLE SUPPORT, HIS CONTINUOUS INTEREST AND UNFAILING GUIDANCE WERE MUCH APPRECIATED.

IT WAS A PLEASURE TO WORK UNDER THE SUPERVISION OF DR. AISHA ALI FAKIR, ASSISTANT PROFESSOR OF CLINICAL PATHOLOGY, AIN SHAMS UNIVERSITY FOR HER EXCELLENT ADVICE, METICULOUS CARE OF EVERY DETAIL. SHE IS SOMEONE I ADMIRE FOR HER ENORMOUS KNOWLEDGE AND HELP OFFERED TO MY WORK.

I SHOULD LIKE TO EXPRESS MY GRATITUDE TO DR. AFAT ABDEL AZIZ ABD EL-GHAFFAR, LECTURER OF CLINICAL PATHOLOGY, AIN SHAMS UNIVERSITY FOR HER EFFORT AND ASSISTANCE IN THE PRACTICAL PART OF THE WORK.

I AM ALSO DEEPLY INDEBTED TO DR. AZZA ABDEL-GAWAD, LECTURER OF PEDIATRICS, AIN SHAMS UNIVERSITY FOR HER GREAT HELP AND METICULOUS SUPERVISION OF THIS WORK.

I WISH TO EXPRESS MY DEEPEST GRATITUDE TO PROF. DR. ENAS EL-ATTAR, PROFESSOR OF CLINICAL EPIDEMIOLOGY AND MEDICAL STATISTICS AT THE NATIONAL CANCER INSTITUTE, CAIRO UNIVERSITY FOR HER GREAT HELP IN ACCOMPLISHMENT OF THIS WORK STATISTICS.

FINALLY I WISH TO THANK ALL MY COLLEAGUES, PATIENTS AND THEIR FAMILIES AT THE HEMATOLOGY/ONCOLOGY CLINIC, CHILDREN HOSPITAL, AIN SHAMS UNIVERSITY AND MEMBERS OF TUMOR MARKERS DEPARTMENT FOR THEIR ENCOURAGEMENT AND ENORMOUS HELP DURING THE PRACTICAL PART OF THIS WORK.

CONTENTS

Chapter	Page
I- INTRODUCTION AND AIM OF THE WORK	1
II- REVIEW OF LITERATURE	3
1- Definition	3
2- Molecular Basis of Thalassemia	3
3- Clinical Manifestations	6
4- Diagnosis	9
5- Treatment	12
6- Course and Prognosis	19
7- Immunity and infection in β -thalassemia	20
8- Cytokines	25
9- Interleukin-8 (IL-8)	29
III- MATERIAL AND METHODS	37
1- Clinical Assessment	38
2- Laboratory Investigations	39
3- Statistical Methods	44
IV- RESULTS	45
V- DISCUSSION	74
VI- CONCLUSION AND RECOMMENDATIONS	79
VII- SUMMARY	81
VIII- REFERENCES	83
IX- ARABIC SUMMARY	108

LIST OF TABLES

Table	Page
* Table * : Cytokine families and examples of their members	26
1- Clinical and laboratory findings of control group	46
2- Clinical and laboratory findings of β -thalassemic non-splenectomized group	47
3- Clinical and laboratory findings of β -thalassemic splenectomized group . . .	48
4- Growth parameters in thalassemic patients and control group	49
5- Statistical analysis and comparison between the hematological results of control and study groups	50
6- Comparison between 3 groups as regards IL-8 and parameters of infection (neutrophils, CRP, % phagocytosis by candida	52
7- Interleukin-8 levels in relation to sex among patients	58
8- Interleukin-8 levels in relation to amount of blood transfusion	61
9- Comparison between control, splenectomized and non-splenectomized groups as regards liver function test: Alanine Transaminase (ALT).	62
10- Interleukin-8 in relation to severity of infection	68

LIST OF FIGURES

Figure	Page
1- Comparison between 3 groups as regards serum interleukin-8 level	53
2- Comparison between patient groups as regards amount of blood transfused .	55
3- Relationship between interleukin-8 level and age in thalassemia patients . .	57
4- Relationship between interleukin-8 level and amount of blood transfused in thalassemia patients (groups B and C)	59
5- Interleukin-8 level in relation to amount of blood transfused in patients groups	60
6- Relationship between interleukin-8 level and ALT	63
7- Relationship between interleukin-8 level and liver size in cm below costal margin	64
8- Interleukin-8 level in relation to severity of infection in patient groups . . .	66
9- Relationship between interleukin-8 level and phagocytosis activity by candida	69
10- Relationship between interleukin-8 level and CRP	70
11- Relationship between interleukin-8 level and total leucocytic counts	71
12- Relationship between interleukin-8 level and neutrophil counts	72

LIST OF ABBREVIATIONS

ALT	Alanine transaminase
α	Alpha
ANOVA	Analysis of variance procedures
β	Beta
BECGF	β endothelial cell growth factor
BMT	Bone marrow transplantation
C	Complement
CBC	Complete blood count
CIC	Circulating immune complex
CRP	C-reactive protein
CT	Connective tissue
DF	Desferrioxamine
DNA	Deoxyribonucleic acid
ELISA	Enzyme linked immunosorbant assay
EPO	Erythropoietin
FGF	Fibroblast growth factor
G-CSF	Granulocyte colony-stimulating factor
G-proteins	Guanine nucleotide binding protein
GDP	Guanine diphosphate
gm/dl	Gram per deciliter
GM-CSF	Granulocyte-macrophage colony-stimulating factor
GOT	Glutamic-oxaloacetic transaminase

GPT	Glutamic pyruvic transaminase
GRO	Proteins that attract and activate neutrophils
GTP	Guanine triphosphate
Hb	Haemoglobin
HLA	Human leukocyte antigen
IFN	Interferon
Ig	Immunoglobulin
IL	Interleukin
IV	Intravenous
LAM	Lectin adhesion molecule
LDH	Lactic acid dehydrogenase
LDNAP	Lymphocyte derived neutrophil activating peptide.
M-CSF	Macrophage colony stimulating factor
Mac-I	Macrophage-I
MCH	Mean corpuscular haemoglobin
MCV	Mean corpuscular volume
MDNAP	Monocyte derived neutrophil activating peptide
MDNCF	Monocyte derived neutrophil chemotactic factor
μ l	Microliter
mg/kg	Milligram per kilogram
MGSA (gro)	Melanoma growth stimulating activity
ml	Milliliter
mRNA	messenger Ribonucleic acid
NAF	Neutrophil activating factor
NAP	Neutrophil activating peptide

nm	Nanometer
PDGF	Platelet derived growth factor
pg	Picogram
PKC	Protein kinase C
PMNL	Polymorphonuclear leucocytes
RES	Reticuloendothelial system
rh	Recombinant human
RNA	Ribonucleic acid
SAS	Statistical analysis system
SC	Subcutaneous route
SHAM	Salicyl hydroxamic acid
T-cells	Thymus derived lymphocytic cells
TGF	Recombinant human latency associated peptide
TNF	Tumour necrosis factor

INTRODUCTION AND AIM OF THE WORK

INTRODUCTION

Thalassemias are a group of disorders occurring frequently in the mediterranean region, the middle east, south east Asia and was first described in Egypt by *Diwany in 1944*.

Khalifa et al (1992) reported a relative frequency of 52.72/100,000 attendants of the outpatient hematology clinic of children hospital, Ain Shams University, to be β -thalassemic, constituting 47.7 % of the hemolytic anemic patients.

The carrier rate in Egypt varied between 2.1 % and 4.5 % in the studies of *Hashim (1978) and Afifi (1987)*.

In 1988 Khalifa et al., reported that thalassemic patients have defective humoral and cellular immunity with increased liability to repeated infections.

Takahashi et al. and Ugucioni et al. in 1993 reported increased level of Interleukin-8 (IL-8) or neutrophil activating peptide-1 as a potent chemotactic stimulus and a major mediator of the acute inflammatory response found in β -thalassemic patients.

AIM OF THE WORK

The aim of the present study is to measure the serum level of interleukin-8 in Egyptian β -thalassemic children and correlate its level to different parameters specially liability to infection and phagocytosis.

REVIEW OF LITERATURE